Diabetic Peripheral Neuropathy - Pipeline Review, H1 2018

Detailed TOC of Diabetic Peripheral Neuropathy - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Peripheral Neuropathy - Overview
Diabetic Peripheral Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Peripheral Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Celgene Corp
Commence Bio Inc
Grunenthal GmbH
Immune Pharmaceuticals Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Novaremed Ltd
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
ViroMed Co Ltd
Diabetic Peripheral Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + triclocarban) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNV-222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNV-2197944 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
donaperminogene seltoplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-8554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for CNS Disorders, Toxicology and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Peripheral Neuropathy - Dormant Projects
Diabetic Peripheral Neuropathy - Discontinued Products
Diabetic Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Oct 30, 2017: VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM202
Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage
Sep 08, 2016: ViroMed proceeding with the